Targeting the cell cycle in esophageal adenocarcinoma: An adjunct to anticancer treatment

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 16

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

404

HTML

4794

Figures (1-2)

298

Tables (1-1)

256

Sum=5752

Apr 28, 2011 (publication date) through Feb 1, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastroenterol. Apr 28, 2011; 17(16): 2063-2069
Published online Apr 28, 2011. doi: 10.3748/wjg.v17.i16.2063

Table 1 Compounds targeting the cell cycle under active development

Inhibitor	Main target	Sponsor	Clinical trials
BI2536	PLK1 (partial inhibition of PLK2/3)	Boehringer Ingelheim	Phase II pancreatic cancer
Danusertib (Formerly PHA-739358)	Pan-aurora kinase inhibitor	Pfizer Italia	Phase II advanced solid tumors
MLN8237	Aurora a inhibitor	Millennium	Phase I/II advanced solid tumours
BI6267	PLK1 inhibitor	Boehringer Ingelheim	Phase II ovarian cancer/phase I advanced solid tumors
P276-00	Small molecule cyclin inhibitor	Piramal Life Sciences	Phase I advanced malignancy/phase II head and neck malignancy
NMS-1286937	PLK1 selective inhibitor	Nerviano Medical Sciences	Phase I advanced solid tumours
P1446A-05	CDK selective inhibitor	Piramal Life Sciences	Phase I advanced malignancy
SCH727965	CDK inhibitor	Schering–Plough	Phase I advanced malignancy
Seliciclib (Roscovitine)	CDK inhibitor	Cyclacel Pharmaceuticals	Phase I advanced malignancy

CDK: Cyclin-dependent kinase; PLK1: Polo-like kinase 1.

Citation: Dibb M, Ang YS. Targeting the cell cycle in esophageal adenocarcinoma: An adjunct to anticancer treatment. World J Gastroenterol 2011; 17(16): 2063-2069
URL: https://www.wjgnet.com/1007-9327/full/v17/i16/2063.htm
DOI: https://dx.doi.org/10.3748/wjg.v17.i16.2063